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Inhalation of high concentrations of certain
nickel-containing dusts in past nickel reﬁning
operations has been associated with increased
respiratory cancer risks (1). However, the
presence of mixed exposures to various chemi-
cal species of nickel (2) as well as other con-
founders made it difficult to identify the
carcinogenic nickel species based on the epi-
demiologic data. Animal inhalation studies
have conﬁrmed the carcinogenicity of certain
nickel compounds (e.g., nickel subsulfide,
high-temperature nickel oxide) but failed to
indicate any carcinogenic potential for a
water-soluble nickel compound (nickel sulfate
hexahydrate) (3).
The different physicochemical properties
and biological effects among categories of
nickel compounds suggest that health assess-
ments for each of these categories are needed.
The carcinogenicity assessment of water-solu-
ble nickel compounds has proven to be partic-
ularly difficult. This can be illustrated by
reviewing the carcinogenicity listing decisions
of several organizations within the last few
years. In 1998, the U.S. National Toxicology
Program (NTP) began consideration of the
proper carcinogenicity classiﬁcation for all cat-
egories of nickel compounds. This was part of
the process leading to a possible revision of the
listing of these compounds in the NTP’s
Ninth Report on Carcinogens (4). During their
discussions, the NTP Review Groups 1 and 2
as well as its Board of Scientific Counselors
subcommittee voted to list “all nickel com-
pounds” (including soluble nickel compounds)
as “known to be human carcinogens” (1) (the
listing recommendation has not yet been
made ﬁnal through publication in the Report
on Carcinogens). That same year, the American
Conference of Governmental Industrial
Hygienists published revised threshold limit
values for the main categories of chemical
nickel species and assigned to them different
carcinogenic classifications. Although nickel
subsulfide and water-insoluble nickel com-
pounds were classified as category A1 (con-
firmed human carcinogen), water-soluble
nickel compounds received a category A4 clas-
siﬁcation (not classiﬁable as a human carcino-
gen) (5). Similar contrasting assessments were
made the following year. In 1999, Beraterkreis
Toxikologie in Germany recommended a cat-
egory C1 classiﬁcation (substances known to
be carcinogenic to man) for water-soluble
nickel compounds (6), whereas the
Toxicological Excellence in Risk Assessment
group conducting a risk assessment for Health
Canada, U.S. Environmental Protection
Agency, and the Metal Finishers Association
of Southern California concluded that the
“carcinogenicity of soluble nickel compounds
cannot be determined” (7,8).
The main reason for these discrepancies lies
in the contradictory ﬁndings provided by the
epidemiologic, animal and in vitro genotoxicity
data. Without a unifying mechanism that can
account for these discrepancies and integrate
them into a single model for nickel respiratory
carcinogenesis, the assessments will continue to
vary widely depending on whether more
emphasis is given to the human or the animal
data and how these data are interpreted.
In this article, the main features of the epi-
demiologic data pertaining to soluble nickel
compounds are presented. Based on the
human data, two possible hypotheses about
the carcinogenic potential of soluble nickel
compounds are considered. The animal and
in vitro data for soluble nickel compounds are
brieﬂy reviewed, evaluating their consistency
with the possible hypotheses. A model for the
respiratory carcinogenicity of nickel com-
pounds is brieﬂy reviewed and the predicted
carcinogenic potential for soluble nickel com-
pounds based on this model is considered.
Finally, an assessment of carcinogenicity of
soluble nickel compounds based on the
weight of evidence from the human, animal,
and mechanistic data is presented. This review
is not meant to be exhaustive and in some
cases only representative references are cited.
Human Data
Human epidemiologic evidence has indicated
an association between increased risk of respira-
tory cancers and inhalation exposures to reﬁn-
ery dust containing a mixture of water-soluble
and water-insoluble nickel compounds
(1,9–11). Soluble nickel (Ni) exposures appear
to increase respiratory cancer risks at lower
exposure concentrations (>1 mg Ni/m3 work-
place dust) than more water-insoluble nickel
compound exposures (>10 mg Ni/m3 work-
place dust) (1). However, the ability of epi-
demiologic studies to determine whether
soluble nickel compounds had a causal role or
rather an enhancing role on the observed excess
tumor incidence is limited by the poor quality
of existing exposure data, inconsistent results
across cohorts, and the presence of mixed expo-
sures to water-insoluble nickel compounds
(e.g., sulfidic and oxidic nickel compounds)
and other confounders with known or sus-
pected carcinogenic potential (e.g., soluble
cobalt compounds, arsenic, acid mists, poly-
cyclic aromatic hydrocarbons, cigarette smoke,
etc.). Standard mortality ratios among groups
of workers are less consistent across cohorts
with predominantly soluble nickel exposures
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than across cohorts with predominantly insolu-
ble nickel exposures. Moreover, there is no con-
sistent dose response with increasing
concentrations of soluble nickel (1). A recent
update of one of these cohorts has indicated a
synergistic response between exposure to nickel
compounds and cigarette smoking in the
induction of lung tumors (10). A study of
nickel platers exposed to predominantly soluble
nickel compounds (no sulﬁdic or oxidic nickel
exposures) did not show increased respiratory
cancer risks (12). Unfortunately, the small size
of the cohort and the relatively low exposure
levels diminish the power of the nickel platers’
study to conclusively evaluate the carcinogenic
potential of soluble nickel compounds.
Therefore, from the human data alone,
two hypotheses can be derived, that soluble
nickel compounds either a) are respiratory car-
cinogens with greater potency than any of the
water-insoluble nickel compounds (e.g., nickel
subsulﬁde) or b) are not complete carcinogens,
but at exposure levels that result in chronic res-
piratory toxicity, they can enhance the respira-
tory carcinogenicity associated with concurrent
inhalation exposures to carcinogens.
Given that water-soluble nickel compounds
are more toxic by inhalation than insoluble
ones, both hypotheses are consistent with
increased respiratory cancer risks seen at lower
exposure levels of soluble (>1 mg Ni/m3) than
insoluble (>10 mg Ni/m3) nickel compounds.
Animal Data
Well-conducted inhalation studies in rats and
mice, where exposures were solely to nickel sul-
fate hexahydrate, failed to demonstrate a car-
cinogenic potential for this compound (3).
Similar negative results were seen in animal
studies through oral exposure (13–15) and
intramuscular injection studies with soluble
nickel compounds alone (16–19). One trans-
placental carcinogenicity study in rats with sol-
uble nickel alone showed signiﬁcant induction
of pituitary tumors in offspring of exposed rats
(20). However, the doses used in this study
were highly toxic to the mothers and may have
resulted in abnormal hormonal imprinting of
the fetuses. Pituitary tumors can occur as a con-
sequence of hormonal disruption in the rat
(21). This ﬁnding was not reproduced in any of
the other studies done with soluble nickel or in
another transplacental carcinogenicity study
conducted with nickel subsulﬁde (22), raising
doubts about the relevance of this study for
evaluating human carcinogenic potential.
Interestingly, oral or injection animal
studies in which soluble nickel was adminis-
tered in combination with a carcinogen suggest
a possible tumor-enhancing effect that mani-
fests in the kidney, the target organ for sys-
temic nickel toxicity (23,24). Again, the results
suggest that chronic toxicity induced by solu-
ble nickel can, under certain circumstances,
result in enhancement of tumorigenicity of
carcinogenic substances.
Rat inhalation studies are very important
to evaluate the human respiratory carcino-
genic potential of nickel compounds. Rats are
a nickel-responsive species (tumors can be
induced by inhalation of nickel subsulﬁde and
green nickel oxide), and inhalation studies are
the only studies that take into account all the
factors that contribute to the bioavailability of
nickel at nuclear sites of target cells in the res-
piratory tract. Therefore, it is worth address-
ing some design issues regarding the negative
NTP nickel sulfate hexahydrate study (3). 
It has been suggested by some groups that
the highest concentration used in the rat 2-year
cancer bioassay [0.1 mg Ni/m3; mass median
aerodynamic diameter (MMAD), 2.2 µm] was
below the maximum tolerated dose and that if
a higher concentration had been tested, a posi-
tive tumorigenic response might have been
found. As is typical, the 2-year bioassay concen-
trations were selected based on the results from
the subchronic studies, and those results
showed similar toxicities for 0.1 mg Ni/m3 of
nickel sulfate hexahydrate or nickel subsulﬁde.
Nevertheless, the tumorigenic responses were
quite different, with a positive response for lung
tumor induction for nickel subsulfide and a
negative response for nickel sulfate [see discus-
sion of this issue by Haber et al. (7)]. In addi-
tion, the use of higher doses of nickel sulfate
would have been precluded if the dose response
for whole-animal toxicity (i.e., mortality) in rats
were very steep. In a recent subchronic study
designed to expose rats to 0.4 mg Ni/m3
(MMAD, 1.9 µm) for 13 weeks, 12 of 39 rats
(31%) died during the second week of expo-
sure (25). The highest concentration was then
reduced to 0.2 mg Ni/m3, and new animals
were added to the study. These toxicity results
conﬁrm a steep dose response for toxicity/mor-
tality and indicate that for a 2-year study
(rather than a 13-week exposure period), a con-
centration below 0.2 mg Ni/m3 would need to
be selected. Otherwise, decreased survival
would diminish rather than increase the
chances of detecting tumors with reasonable
power. Therefore, these results conﬁrm that the
0.1 mg Ni/m3 highest exposure level used in
the 2-year NTP bioassay was indeed at or near
the maximum tolerated dose.
It also has been noted that the highest con-
centration to which rats were exposed in the
NTP bioassay was 0.1 mg Ni/m3 (MMAD,
2.2 µm), whereas workers showing excess res-
piratory cancer risks experienced soluble nickel
exposures above 0.1 mg Ni/m3 (workplace
dust). Some have suggested that this difference
in exposure levels could explain why rats did
not get tumors whereas some workers did. In
considering this point, it is important to note
that the aerosol used in the NTP studies had
particles of a MMAD of 2.2 µm. In contrast,
the particle size distribution of the aerosols in
the workplace is broader and characterized by
coarser particles (e.g., MMAD > 30–50 µm).
Particles in the 2 µm range comprise less than
10% of the workplace dust. Therefore, for a
proper comparison between animal and
human exposures, the particle size of the
aerosols as well as deposition/clearance differ-
ences between animals and humans must be
taken into consideration. An animal-to-human
extrapolation study based on deposition/clear-
ance models for rat and human lungs allows
calculation of equivalent exposures (26–28).
These results indicate that after accounting for
particle size distribution, the soluble nickel
exposure levels that did not induce tumors in
rats are indeed equivalent (in terms of nickel
lung burden) to those experienced by workers
in the nickel refinery epidemiologic studies
(Figure 1) [see further discussion of this issue
by Haber et al. (7)].
In summary, the weight of evidence based
on the animal data argues against hypothesis
(a) that soluble nickel compounds by them-
selves are carcinogens of higher potency than
water-insoluble nickel compounds. Rather, it
supports hypothesis (b) that soluble nickel
compounds by themselves are not carcino-
genic but that at concentrations above those
that result in chronic respiratory toxicity, they
may enhance the carcinogenicity of simulta-
neous inhalation exposure to carcinogens.
In Vitro Studies
In vitro, soluble nickel compounds induce
essentially the same genotoxic effects as water-
insoluble nickel compounds (e.g., nickel sub-
sulﬁde) but with lower potency (29–31). The
higher concentrations required to see these
effects with soluble nickel compounds are
attributed to the less efﬁcient cellular uptake
of Ni2+ ion from soluble than from insoluble
nickel compounds. For example, the percent-
ages of nickel in the nucleus of Chinese ham-
ster ovary cells exposed to nickel sulfide/
subsulﬁde are up to 300- to 500-fold higher
than the percentage levels of Ni2+ in the
nucleus of cells exposed to equivalent levels of
nickel chloride (32,33).
In vitro results indicate a potential for solu-
ble nickel compounds to cause genotoxic
effects (when sufﬁcient amounts reach the cell
nucleus) and, in that respect, are consistent
with a possible carcinogenic effect of soluble
nickel compounds [hypothesis (a)]. However,
based on the in vitro results, soluble nickel
compounds would be expected to have a much
lower carcinogenic potency than insoluble
nickel compounds, which is inconsistent with
the human data. The in vitro results also are
consistent with hypothesis (b) discussed above
(soluble nickel compounds by themselves are
not carcinogenic) when the differences
between in vitro and in vivo exposures are
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taken into account. Specifically, there are
active clearance mechanisms in vivo that are
absent in a petri dish. Because there is no clear-
ance, prolonged in vitro exposures to soluble
nickel compounds at high enough levels even-
tually allow some Ni2+ ion to reach the cell
nucleus. In vivo, however, this is precluded by
the rapid lung clearance that has been observed
in experimental animals and humans
(3,34,35). To achieve sufﬁciently high concen-
trations of Ni2+ ion at respiratory tract target
sites would require animals to be exposed to
concentrations that likely would result in
severe toxicity and death. In summary, results
from in vitro studies tend to favor hypothesis
(b), although hypothesis (a) cannot be totally
disregarded based solely on in vitro data.
Research conducted in the last few years
has focused on the effects of nickel ions on
gene expression [see review by Salnikow and
Costa (36)]. In vitro exposure of certain cell
types to speciﬁc concentrations of nickel com-
pounds has been shown to affect the levels of
thrombospondin 1 and hypoxia-inducible
transcription factor-1 (HIF-1) (37,38).
Induction of yet another set of proteins such as
Cap43 (yet unknown function), vascular
endothelial growth factor, plasminogen activa-
tor inhibitor-1, and erythropoeitin seems to be
mediated by the effects of nickel on HIF-1
(39–42). These signal transduction effects
appear to be independent of the genotoxic
(nuclear) effects of nickel because they can be
equally elicited by both soluble and insoluble
nickel compounds. These nickel-induced
changes in gene expression could play a role in
the in vivo tumorigenicity and/or tumor
enhancement effects seen with nickel com-
pounds. Animal studies are now needed to
evaluate whether some of these in vitro effects
are related to site-speciﬁc carcinogenic effects,
site-specific toxic effects, or even possible
homeostatic functions of nickel ions.
Respiratory Model for Nickel
Carcinogenesis
Even though some changes in gene expression
may be elicited at the cell membrane level,
many of the nickel effects associated with cell
transformation and carcinogenesis depend on
the presence of nickel in the cell nucleus (35).
A model for nickel carcinogenesis can be
based on the assessment of the bioavailability
of nickel ion at nuclear sites of respiratory tar-
get cells (7,43–45). This model predicts that
it is not just the presence of nickel in a given
inhaled substance that determines its carcino-
genic potential but rather whether this nickel
is bioavailable in sufficient amounts at
nuclear sites of epithelial cells to result in res-
piratory tumor induction. The factors that
influences this bioavailability and thus the
intrinsic hazard of a substance include parti-
cle size, surface characteristics, mechanism of
clearance from the respiratory tract, mecha-
nism of uptake into target cells, respiratory
and whole animal toxicity, and solubility (rel-
ative ease of Ni2+ ion release) (Figure 2).
The particle size of the inhaled dust not
only will affect respiratory tract deposition but
also will inﬂuence clearance of the particles and
uptake into target cells (46). Surface area and
surface charge also may affect clearance mecha-
nisms and uptake by target cells (47). Uptake
of water-insoluble nickel particles via phagocy-
tosis is an efﬁcient mechanism to deliver nickel
to target cells, whereas uptake of nickel ions
derived from soluble nickel compounds (or
from dissolution of more insoluble compounds
outside the cells) is not (48). Ni2+ ion release
rates from water-insoluble nickel compounds
inside the cells also inﬂuence the bioavailability
of Ni2+ ion derived from dissolution of
phagocitized particles at nuclear sites (33).
Water solubility of inhaled nickel compounds
appears to be directly related to whole animal
toxicity and to some extent to respiratory
toxicity as well (3,34).
As a result of these interactions, the nickel
species that have the greatest potential to
induce tumors are those that a) are insoluble
enough to be present in the lung as particles,
b) can get into epithelial cells via phagocytosis,
and c) once inside the phagosomes, release
high levels of Ni2+ ion (49). An example of
such a compound is nickel subsulfide. This
compound is partially soluble in biological
ﬂuids and is taken up by cells with ease. Inside
the cells, because of the acidic pH of phago-
somes, high levels of nickel ions are released
and delivered to nuclear sites. In addition, its
partial solubility in biological ﬂuids results in
relatively high levels of respiratory toxicity,
with increased cell proliferation (25) that may
contribute to tumor formation. For this com-
pound, the human and animal data consis-
tently indicate a respiratory carcinogenic
potential and confirm the genotoxic effects
seen in in vitro studies. Most organizations are
in agreement in classifying nickel subsulﬁde as
a known human carcinogen.
By contrast, water-soluble nickel com-
pounds immediately dissociate into Ni2+ ions
and counter ions upon inhalation. Uptake of
Ni2+ ions into the cells is very inefﬁcient and
further impaired by the rapid clearance of Ni2+
ions from the lung and the high-afﬁnity bind-
ing of Ni2+ ions to proteins (45). This model
predicts that soluble nickel compounds should
have much lower carcinogenic potency than
water-insoluble nickel compounds. In theory,
if the inhaled concentrations of soluble nickel
compounds were high enough, sufficient
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Figure 1. Equivalent rat and human exposure levels to nickel sulfate (NiSO4)
hexahydrate that result in similar nickel lung burdens using a deposition/clear-
ance model developed by Yu and colleagues (26,28). Abbreviations: da, particle
aerodynamic diameter; σ g, geometric standard deviation; γ 1, fraction of parti-
cles with da1 and σ g1; and γ
2, fraction of particles with da2 and σ g2. (A) Considers
the human aerosol as having the same particle size distribution as the animal
aerosol (da = 2.3 µm). (B) Considers the real workplace size distribution of the
human aerosol rather than the one in the animal aerosol. 
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Figure 2. Interactions of nickel compounds with epithelial (target) cells in the
bronchioalveolar region of the lung. Modiﬁed from Oller et al. (45).Ni2+ ion should reach the nucleus of target
cells. In practice, however, this is not possible
because of the toxicity of the Ni2+ ion that
results in high animal mortality at concentra-
tions below those required for a tumorigenic
effect (3). Therefore, inhalation of soluble
nickel compounds does not result in suffi-
ciently high bioavailable nickel at nuclear tar-
get sites to induce tumors. However, as
discussed for nickel subsulﬁde, soluble nickel
compounds can cause respiratory toxicity and
may enhance the carcinogenicity of other com-
pounds, perhaps through some of the recently
identiﬁed cell signaling pathways (36).
As discussed above, only inhalation stud-
ies can be used to ascertain the respiratory
carcinogenic potential of nickel-containing
substances because only inhalation studies
take into account all the factors that inﬂuence
Ni2+ ion bioavailability and carcinogenic
potential. In summary, mechanistic informa-
tion supports hypothesis (b) (i.e., soluble
nickel compounds by themselves are not car-
cinogenic but that at concentrations above
those that result in chronic respiratory toxic-
ity they may enhance the carcinogenicity of
inhalation exposure to carcinogens).
Overall Assessment 
of Carcinogenicity
The weight of evidence from the combined
analysis of human, animal, and in vitro data
considered within the current model of respi-
ratory carcinogenicity of nickel indicates that
inhalation of soluble nickel compounds
(alone) is not expected to result in human
carcinogenicity. However, the human and
animal data suggest that at concentrations
that result in chronic toxicity, soluble nickel
compounds may enhance the tumor response
elicited by inhalation of carcinogens such as
nickel subsulﬁde or cigarette smoke. Further
support for this assessment comes from using
animal inhalation data (in which chronic lung
inflammation is considered a surrogate for
tumor-enhancing effects) to extrapolate respi-
ratory cancer risks for humans. The calcu-
lated risks, based on the assumption that any
possible respiratory tumor-enhancing effect of
soluble nickel is due to chronic respiratory
toxicity, are in general agreement with the
risks observed in epidemiologic studies (50).
Different hazard identification programs
employ different (although generally similar)
criteria to classify substances as carcinogens.
In any of these programs, however, one would
not expect a chemical that by itself does not
cause cancer to be classified as a known
human carcinogen. Within each classiﬁcation
system, the proper label for substances that by
themselves are demonstrated not to be car-
cinogens (in sensitive animal species) but may
at high enough concentrations enhance the
carcinogenic risk associated with inhalation
exposure to other substances will need to be
considered. This has important implications
in terms of risk assessment because it suggests
that if exposures to soluble nickel compounds
are kept below the levels that cause chronic
respiratory toxicity, any possible tumor-
enhancing effects (particularly in smokers)
would be avoided.
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